| Slide Lecture Programs |
| 2006 Core Curriculum |
| Antiplatelet Interventions in ACS |
March 10, 2006
|
| II: |
Thrombus Susceptibility and the Vulnerable Plaque" width="220" height="147" border="0">
Thrombus Susceptibility and the Vulnerable Plaque
|
|
 |
|
 |
|
 |
18 |
 |
| |

Interaction between inflammation and hemostasis in vulnerable plaque
|
|
 |
|
 |
|
 |
19 |
 |
| |

Txnip links shear stress to inflammation
|
|
 |
|
 |
|
 |
20 |
 |
| |

Platelet adhesion and aggregation
|
|
 |
|
 |
|
 |
21 |
 |
| |

Platelets release soluble CD40 ligand (sCD40L) after thrombin stimulation
|
|
 |
|
 |
|
 |
22 |
 |
| |

Recombinant sCD40L enhances platelet release of reactive oxygen species
|
|
 |
|
 |
|
 |
23 |
 |
| |

GP IIb/IIIa antagonists block sCD40L release from platelets
|
|
 |
|
 |
|
 |
24 |
 |
| |

Points of action for antithrombotics
|
|
 |
|
 |
|
 |
25 |
 |
| |

Proposed model for optimal use of GP IIb/IIIa inhibitors
|
|
 |
|
 |
|
 |
26 |
 |
| |

Potential mechanisms for reduction of thrombo-inflammation with GP IIb/IIIa inhibition
|
|
 |
|
 |
|